BOSTON – February 18, 2025 –

波士顿——2025年2月18日——

Foundation Medicine, Inc.

基石医学公司

, a genomics company committed to transforming cancer care, today announced a collaboration with Sumitomo Pharma America, Inc. (SMPA) to develop the FoundationOne®Heme platform as a companion diagnostic to identify patients with acute leukemia with a

，一家致力于改变癌症治疗的基因组学公司，今天宣布与住友制药美洲公司（SMPA）合作，开发FoundationOne®Heme平台作为伴随诊断工具，以识别急性白血病患者中的特定群体。

KMT2A

KMT2A

rearrangement, also known as mixed lineage leukemia (MLL) rearrangement, or

重排，也称为混合谱系白血病（MLL）重排，或

NPM1

NPM1

mutations for potential treatment with SMPA’s enzomenib (DSP-5336), an investigational menin inhibitor.

潜在治疗的突变适用于SMPA的恩佐美尼（DSP-5336），一种研究中的menin抑制剂。

Acute leukemia requires immediate treatment as the blood cells multiply rapidly, leading to a sudden onset of symptoms.

急性白血病需要立即治疗，因为血液细胞迅速增殖，导致症状突然发作。

1

1

Approximately 30% of acute myeloid leukemia (AML) patients have

大约30%的急性髓系白血病（AML）患者有

NPM1

NPM1

mutations,

突变，

2

2

and 5-10% of AML patients have

并且5-10%的AML患者有

KMT2A

KMT2A

(MLL) rearrangements.

（MLL）重排。

3

3

Menin inhibitors are emerging as a promising targeted therapy option for acute leukemia with

Menin抑制剂正成为急性白血病的一种有前景的靶向治疗选择，

KMT2A

KMT2A

(MLL) rearrangements or

(MLL) 重排或

NPM1

NPM1

mutations.

突变。

4

4

Menin is a protein that interacts with the

Menin是一种与之相互作用的蛋白质

KMT2A

KMT2A

gene, playing a crucial role in regulating gene expression and protein interactions involved in hematopoiesis.

基因，在调控造血过程中基因表达和蛋白质相互作用方面发挥关键作用。

5

5

Menin inhibitors are designed to disrupt this interaction, inhibiting the proliferation of leukemic cells.

Menin抑制剂旨在破坏这种相互作用，抑制白血病细胞的增殖。

4

4

“Thanks to advancements in comprehensive genomic profiling, we have seen an increased focus on developing new targeted therapies for patients with hematological malignancies, which may help bring the promise of precision medicine to more patients,” said Foundation Medicine’s Chief Biopharma Officer Troy Schurr.

“由于综合基因组分析技术的进步，我们看到针对血液系统恶性肿瘤患者开发新靶向疗法的关注度有所提高，这可能有助于让更多患者实现精准医疗的承诺，”Foundation Medicine的首席生物医药官Troy Schurr说道。

“We’re excited to work with Sumitomo to advance our FoundationOne Heme platform as a companion diagnostic as they advance investigation of this promising potential treatment option for acute leukemia patients with a .

“我们很高兴与住友合作，推进我们的FoundationOne Heme平台作为伴随诊断，因为他们在研究这种针对急性白血病患者的有潜力的治疗方案。”

KMT2A

KMT2A

rearrangement and

重新排列和

NPM1

NPM1

mutations.”

突变。”

Foundation Medicine’s portfolio of tests offers physicians both blood- and tissue-based testing options for detecting genomic alterations that help guide personalized treatment decisions. Foundation Medicine is the global leader in companion diagnostic approvals, with more than 50% of all approved companion diagnostic indications for next-generation sequencing (NGS) testing in the United States and Japan..

Foundation Medicine的检测产品组合为医生提供了血液和组织两种检测选项，以检测基因组变异，帮助指导个性化治疗决策。Foundation Medicine是伴随诊断批准的全球领导者，在美国和日本，超过50%的下一代测序（NGS）检测的伴随诊断指征都得到了批准。

6

6

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Foundation Medicine® 和 FoundationOne® 是 Foundation Medicine, Inc. 的注册商标。

About Foundation Medicine: Your Essential Partner in Cancer Care

关于基础医学：您在癌症护理中的重要合作伙伴

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines.

Foundation Medicine是癌症分子分析领域的先驱，致力于塑造临床护理和研究的未来。我们与癌症领域的广泛合作伙伴携手合作，力求在质量、科学卓越性和监管领导力方面树立标杆。我们对癌症生物学的深刻理解帮助医生为患者做出明智的治疗决策，并助力研究人员开发新药。

Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on .

每一天，我们都在努力帮助我们的合作伙伴寻找答案并采取行动，使世界各地更多的人能够从精准的癌症护理中受益。欲了解更多信息，请访问我们。

www.FoundationMedicine.com

www.FoundationMedicine.com

and follow us on

关注我们

LinkedIn

领英

and

和

X

X

.

。

About FoundationOne®Heme

关于FoundationOne®Heme

FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at .

FoundationOne®Heme 是一种由 Foundation Medicine 开发的实验室检测方法，其性能特征已由该公司确定。FoundationOne Heme 尚未获得美国食品药品监督管理局（FDA）的批准或认证。有关 FoundationOne Heme 的更多信息，请参阅其技术规格。

foundationmedicine.com/heme

foundationmedicine.com/heme

.

。

The test employs RNA sequencing in addition to DNA sequencing to simultaneously detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions.

该测试除了采用DNA测序外，还采用RNA测序，以同时检测所有类型的基因组变异，包括碱基对替换、插入和缺失、拷贝数变异和重排以及基因融合。

Media Contact:

媒体联系人：

Danielle Johns, 845-304-7408

丹妮尔·约翰斯，845-304-7408

newsroom@foundationmedicine.com

新闻编辑室@基础医学.com

1

1

Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. StatPearls [Internet]. January 17, 2023. Accessed November 11, 2024.

Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. 白血病. StatPearls [互联网]. 2023年1月17日. 访问日期：2024年11月11日.

https://www.ncbi.nlm.nih.gov/books/NBK560490/

https://www.ncbi.nlm.nih.gov/books/NBK560490/

2

2

Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple endocrine neoplasia type 1: latest insights. Endocr Rev. 2021;42(2):133-170.

布兰迪 ML，阿加瓦尔 SK，佩里埃 ND，莱恩斯 KE，瓦尔克 GD，塔克 RV。多发性内分泌腺瘤病1型：最新见解。《内分泌学评论》。2021年；42（2）：133-170。

https://doi.org/10.1210/endrev/bnaa031

https://doi.org/10.1210/endrev/bnaa031

3

3

Borkin D, Klossowski S, Pollock J, et al. Complexity of blocking bivalent protein-protein interactions: development of a highly potent inhibitor of the menin-mixed-lineage leukemia interaction. J Med Chem. 2018;61(11):4832-4850.

博金 D，克洛索夫斯基 S，波洛克 J，等。阻断双价蛋白质-蛋白质相互作用的复杂性：开发针对 menin-混合谱系白血病相互作用的高效抑制剂。《药物化学杂志》。2018；61（11）：4832-4850。

https://doi.org/10.1021/acs.jmedchem.8b00071

https://doi.org/10.1021/acs.jmedchem.8b00071

4

4

Thomas X. Small molecule menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther. 2024 Mar;12(1):57-72.

托马斯·X。小分子Menin抑制剂：针对具有KMT2A重排或NPM1突变的急性髓系白血病的新型治疗药物。《肿瘤学治疗》。2024年3月；第12卷第1期：57-72页。

https://doi.org/10.1007/s40487-024-00262-x

https://doi.org/10.1007/s40487-024-00262-x

5

5

Cierpoclo T, Grembecka J. Challenges and opportunities in targeting the menin-MLL Interaction. Future Med Chem. 2014; 6(4):447-462. doi:10.4155/fmc.13.214. https://doi.org/10.4155/fmc.13.214

Cierpoclo T, Grembecka J. 靶向menin-MLL相互作用的挑战与机遇。《未来药物化学》。2014年；6(4):447-462。doi:10.4155/fmc.13.214。https://doi.org/10.4155/fmc.13.214

6

6

Data on File, Foundation Medicine, Inc. 2024

文件中的数据，基础医学公司，2024